Bacterial membrane vesicle (BMV) nanoparticles are secreted naturally by bacteria throughout their lifecycle and are a rich source of biomarkers from the parent bacteria, but they are currently underutilized for clinical diagnostic applications, such as pathogen identification, due to the time-consuming and low-yield nature of traditional recovery methods required for analysis. The recovery of BMVs is particularly difficult from complex biological fluids. Here, we demonstrate a recovery method that uses dielectrophoretic (DEP) forces generated on electrokinetic microfluidic chips to isolate and analyze BMVs from human plasma. DEP takes advantage of the natural difference in dielectric properties between the BMVs and the surrounding plasma fluid to quickly and consistently collect these particles from as little as 25 µL of plasma. Using DEP and immunofluorescence staining of the LPS biomarker carried on BMVs, we have demonstrated a lower limit of detection of 4.31 × 109 BMVs/mL. The successful isolation of BMVs from human plasma using DEP, and subsequent on-chip immunostaining for biomarkers, enables the development of future assays to identify the presence of specific bacterial species by analyzing BMVs from small amounts of complex body fluid.
Protease activity is an emerging biomarker for cancer detection as activity levels are often increased in tumor tissue compared to healthy tissue. Of particular interest is the activity of proteases carried by extracellular vesicle (EV) nanoparticles which are oversecreted by tumors into circulation. Current methods to analyze the activity of proteases bound to EVs require complex multi‐instrument sample processing to separate EVs from plasma to quantify protease activity. This makes EV‐based protease activity detection a challenge for diagnostic or point‐of‐care applications. Here, a method is reported that manipulates EV nanoparticles and charged molecular byproducts from protease activity using two different electrokinetic phenomena generated by a single electrode microarray within a microfluidic channel. Dielectrophoresis is first generated to recover EVs carrying active trypsin‐like proteases from human plasma followed by electrophoresis for subsequent analysis of peptide cleavage products indicating protease activity. This method demonstrates signal amplification through protease catalytic activity in combination with concentrating mechanisms of dielectrophoresis and electrophoresis. Using this approach, a significant difference in protease activity is observed between patients with pancreatic cancer and benign cysts. This demonstrates dual‐electrokinetic chip‐based technology as a useful tool to manipulate different sized and charged analytes in a single device enabling future clinical translation of EV‐based protease diagnostics.
Dielectrophoresis (DEP) is a fast and reliable nanoparticle recovery method that utilizes nonuniform electric fields to manipulate particles based on their material composition and size, enabling recovery of biologically‐derived nanoparticles from plasma for diagnostic applications. When applying DEP to undiluted human plasma, collection of endogenous albumin proteins was observed at electric field gradients much lower than predicted by theory to collect molecular proteins. To understand this collection, nanoparticle tracking analysis of bovine serum albumin (BSA) dissolved in 0.5× phosphate‐buffered saline was performed and showed that albumin spontaneously formed aggregate nanoparticles with a mean diameter of 237 nm. These aggregates experienced a dielectrophoretic force as a function of aggregate radius rather than the diameter of individual protein molecules which contributed to their collection. In high conductance buffer (6.8 mS/cm), DEP was able to move these aggregates into regions of high electric field gradient, and in lower conductance buffer (0.68 mS/cm), these aggregates could be moved into high or low gradient regions depending on the applied frequency. Disruption of BSA aggregates using a nonionic detergent significantly decreased the particle diameter, resulting in decreased dielectrophoretic collection of albumin which increased the collection consistency of particles of interest. These results provide techniques to manipulate albumin aggregates via DEP, which impacts collection of diagnostic biomarkers.
Cancer‐derived extracellular vesicle (EV) nanoparticles carry important biomarkers but are difficult to recover from plasma, making EV‐based diagnostics a challenge for clinical settings. Here, we demonstrate nanoparticle‐based detection of pancreatic cancer using dielectrophoresis (DEP) nanoparticle recovery technology, which purifies nanoparticles from undiluted plasma and quantifies associated biomarkers. We combined both nanoparticle recovery and biomarker quantification on a single device by simultaneously collecting cell‐free DNA nanoparticles and EVs followed by on‐chip biomarker fluorescent staining for DNA and Glypican‐1. Using a blinded cohort, these biomarkers differentiated pancreatic cancer from benign pancreatic diseases, including cysts, pancreatitis, and precancerous low‐grade intraductal papillary mucinous neoplasm (IPMN) lesions, with a sensitivity of 0.92, a specificity of 0.83, and an AUC of 0.93. The AUC increased to 0.97 for patients over 50 years old. This is higher than the standard invasive endoscopic ultrasound‐guided fine needle aspiration tissue biopsy procedure (AUC 0.79). This study is among the first demonstrating a combined threshold of DNA and protein levels that can distinguish pancreatic cancer from its precursor IPMN lesions. We also demonstrated the detection of early‐stage pancreatic cancer and high‐grade in situ precancerous lesions. This DEP‐based technique shows that multiple types of cancer‐derived nanoparticles can be quickly and easily recovered from plasma making it promising for future clinical diagnostics.